2

3

4 5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

Title: Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States Authors: (1) Katherine Adams, MPH* CDC COVID-19 Response Team, Atlanta, Georgia (2) Jillian P. Rhoads, PhD* Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee (3) Diya Surie, MD* CDC COVID-19 Response Team, Atlanta, Georgia (4) Manjusha Gaglani, MBBS Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas (5) Adit A. Ginde, MD, MPH Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado (6) Tresa McNeal, MD Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas (7) Shekhar Ghamande, MD Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas (8) David Huynh, MD Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado (9) H. Keipp Talbot, MD, MPH Departments of Medicine and Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee (10) Jonathan D. Casey, MD, MSci Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (11) Nicholas M. Mohr, MD, MS Department of Emergency Medicine, University of Iowa, Iowa City, Iowa (12) Anne Zepeski, PharmD Department of Emergency Medicine, University of Iowa, Iowa City, Iowa (13) Nathan I. Shapiro, MD, MPH Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts (14) Kevin W. Gibbs, MD Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina (15) D. Clark Files, MD Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina (16) Madeline Hicks, BA Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina (17) David N. Hager, MD, PhD Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland (18) Harith Ali, MBBS Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland (19) Matthew E. Prekker, MD, MPH

48 Department of Emergency Medicine and Medicine, Hennepin County Medical Center, 49 Minneapolis, Minnesota 50 (20) Anne E. Frosch, MD 51 Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota 52 (21) Matthew C. Exline, MD, MPH 53 Department of Medicine, The Ohio State University, Columbus, Ohio 54 (22) Michelle N. Gong, MD 55 Department of Medicine, Montefiore Health System, Albert Einstein College of Medicine, Bronx, 56 New York 57 (23) Amira Mohamed, MD 58 Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, 59 Bronx. New York 60 (24) Nicholas J. Johnson, MD 61 Department of Emergency Medicine and Division of Pulmonary, Critical Care and Sleep 62 Medicine, University of Washington, Seattle, Washington 63 (25) Vasisht Srinivasan, MD 64 Department of Emergency Medicine, University of Washington, Seattle, Washington 65 (26) Jay S. Steingrub, MD 66 Department of Medicine, Baystate Medical Center, Springfield, Massachusetts 67 (27) Ithan D. Peltan, MD, MSc 68 Department of Medicine, Intermountain Medical Center, Murray, Utah and University of Utah, 69 Salt Lake City, Utah 70 (28) Samuel M. Brown, MD, MS 71 Department of Medicine, Intermountain Medical Center, Murray, Utah and University of Utah, 72 Salt Lake City, Utah 73 (29) Emily T. Martin, PhD 74 School of Public Health, University of Michigan, Ann Arbor, Michigan 75 (30) Arnold S. Monto, MD 76 School of Public Health, University of Michigan, Ann Arbor, Michigan 77 (31) Adam S. Lauring, MD, PhD 78 Departments of Internal Medicine and Microbiology and Immunology, University of Michigan, 79 Ann Arbor, Michigan 80 (32) Akram Khan, MD 81 Department of Medicine, Oregon Health and Sciences University, Portland, Oregon 82 (33) Catherine L. Hough, MD 83 Department of Medicine, Oregon Health and Sciences University, Portland, Oregon 84 (34) Laurence W. Busse, MD 85 Department of Medicine, Emory University, Atlanta, Georgia 86 (35) Caitlin C. ten Lohuis, ACNP-BC 87 Emory Critical Care Center, Emory Healthcare, Atlanta, Georgia 88 (36) Abhijit Duggal, MD 89 Department of Medicine, Cleveland Clinic, Cleveland, Ohio 90 (37) Jennifer G. Wilson, MD 91 Department of Emergency Medicine, Stanford University School of Medicine, Stanford, 92 California 93 (38) Alexandra June Gordon, MD 94 Department of Emergency Medicine, Stanford University School of Medicine, Stanford, 95 California

96 (39) Nida Qadir, MD 97 Department of Medicine, University of California-Los Angeles, Los Angeles, California 98 (40) Steven Y. Chang, MD, PhD 99 Department of Medicine, University of California-Los Angeles, Los Angeles, California 100 (41) Christopher Mallow, MD, MHS 101 Department of Medicine, University of Miami, Miami, Florida 102 (42) Carolina Rivas 103 Department of Medicine, University of Miami, Miami, Florida 104 (43) Hilary M. Babcock, MD, MPH 105 Department of Medicine, Washington University, St. Louis, Missouri 106 (44) Jennie H. Kwon, DO, MS 107 Department of Medicine, Washington University, St. Louis, Missouri 108 (45) James D. Chappell, MD, PhD 109 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee 110 (46) Natasha Halasa, MD, MPH Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee 111 112 (47) Carlos G. Grijalva, MD, MPH 113 Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee 114 (48) Todd W. Rice, MD, MSc 115 Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 116 (49) William B. Stubblefield, MD, MPH 117 Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 118 (50) Adrienne Baughman 119 Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 120 (51) Christopher J. Lindsell, PhD 121 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee 122 (52) Kimberly W. Hart, MA 123 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee (53) Sandra N. Lester, PhD 124 125 CDC COVID-19 Response Team, Atlanta, Georgia 126 (54) Natalie J. Thornburg, PhD 127 CDC COVID-19 Response Team, Atlanta, Georgia 128 (55) SoHee Park, BS 129 CDC COVID-19 Response Team, Atlanta, Georgia 130 (56) Meredith L. McMorrow, MD 131 CDC COVID-19 Response Team, Atlanta, Georgia 132 (57) Manish M. Patel, MD 133 CDC COVID-19 Response Team, Atlanta, Georgia (58) Mark W. Tenforde, MD, PhD** 134 135 CDC COVID-19 Response Team, Atlanta, Georgia 136 (59) Wesley H. Self, MD, MPH** 137 Department of Emergency Medicine and Vanderbilt Institute for Clinical and Translational 138 Research, Vanderbilt University Medical Center, Nashville, Tennessee 139 140 For the Influenza and Other Viruses in the Acutely III (IVY) Network*** 141

- *Katherine Adams, Jillian P. Rhoads, and Diya Surie contributed equally to this work as lead author.
- 143 ** Wesley H. Self and Mark W. Tenforde contributed equally to this work as senior author.
- 144 *** A full list of collaborators in the IVY Network is shown in Appendix A in the Supplemental Materials.

Corresponding Author:

- 147 Wesley H. Self, MD, MPH; Vanderbilt University Medical Center; Nashville, Tennessee USA. Email:
- 148 wesley.self@vumc.org.

Second Corresponding Author:

- 151 Katherine Adams, MPH; Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd,
- MS H24-7, Atlanta, Georgia 30329. Email: rqx6@cdc.gov.

154 Funding:

145146

149150

153

159 160

163

166

- Primary funding for this work was provided by the United States Centers Disease Control and Prevention
- 156 (contracts 75D30120F00002 and 75D30122C12914 to Dr. Self). The REDCap data tool used in this work
- 157 was supported by a Clinical and Translational Science Award (UL1 TR002243) from the National Center
- 158 for Advancing Translational Sciences, National Institutes of Health.

Disclaimer:

- The findings and conclusions in this report are those of the authors and do not necessarily represent the
- official position of the Centers for Disease Control and Prevention (CDC).

164 **Key Words**:

- 165 COVID-19; SARS-CoV-2; vaccine effectiveness; attenuation; mRNA vaccines; omicron variant
- 167 Word Counts:
- 168 Abstract: 367
- 169 Main Text: 4373

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

ABSTRACT Objectives: To compare the effectiveness of a primary COVID-19 vaccine series plus a booster dose with a primary series alone for the prevention of Omicron variant COVID-19 hospitalization. Design: Multicenter observational case-control study using the test-negative design to evaluate vaccine effectiveness (VE). **Setting:** Twenty-one hospitals in the United States (US). Participants: 3,181 adults hospitalized with an acute respiratory illness between December 26, 2021 and April 30, 2022, a period of SARS-CoV-2 Omicron variant (BA.1, BA.2) predominance. Participants included 1,572 (49%) case-patients with laboratory confirmed COVID-19 and 1,609 (51%) control patients who tested negative for SARS-CoV-2. Median age was 64 years, 48% were female, and 21% were immunocompromised; 798 (25%) were vaccinated with a primary series plus booster, 1,326 (42%) were vaccinated with a primary series alone, and 1,057 (33%) were unvaccinated. Main Outcome Measures: VE against COVID-19 hospitalization was calculated for a primary series plus a booster and a primary series alone by comparing the odds of being vaccinated with each of these regimens versus being unvaccinated among cases versus controls. VE analyses were stratified by immune status (immunocompetent; immunocompromised) because the recommended vaccine schedules are different for these groups. The primary analysis evaluated all COVID-19 vaccine types combined and secondary analyses evaluated specific vaccine products. Results: Among immunocompetent patients, VE against Omicron COVID-19 hospitalization for a primary series plus one booster of any vaccine product dose was 77% (95% CI: 71-82%), and for a primary series alone was 44% (95% CI: 31–54%) (p<0.001). VE was higher for a boosted regimen than a primary series alone for both mRNA vaccines used in the US (BNT162b2: primary series plus booster VE 80% (95% CI: 73-85%), primary series alone VE 46% (95% CI: 30-58%) [p<0.001]; mRNA-1273: primary series plus booster VE 77% (95% CI: 67-83%), primary series alone VE 47% (95% CI: 30-60%) [p<0.001]). Among

immunocompromised patients, VE for a primary series of any vaccine product against Omicron COVID-19 hospitalization was 60% (95% CI: 41-73%). Insufficient sample size has accumulated to calculate effectiveness of boosted regimens for immunocompromised patients.

Conclusions: Among immunocompetent people, a booster dose of COVID-19 vaccine provided additional benefit beyond a primary vaccine series alone for preventing COVID-19 hospitalization due to the Omicron variant.

BACKGROUND

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

The highly transmissible SARS-CoV-2 Omicron variant, first identified in southern Africa in November 2021, became the dominant variant in the United States (US) by late December 2021. ^{1,2} The surges in COVID-19 cases driven by this variant and its emergent lineages (PANGO BA.1/BA.2) was the largest recognized in the United States, with a peak of over 400,000 cases per day.³ Emerging data on vaccine protection against disease caused by the Omicron variant has been mixed. Early immunological studies showed evidence of immune evasion by the Omicron variant with decreased neutralization from either vaccine sera or monoclonal antibodies compared to previous variants.^{4,5} Recent evidence suggests a rapid decline over time in antibody titers following booster doses.⁶ Real-world studies have shown decreased effectiveness of both primary series and booster doses of COVID-19 vaccine regimens against symptomatic infection, with waning occurring as early as 5–9 weeks after booster dose receipt. 7-⁹ However, results from studies evaluating the protection provided by booster doses against severe COVID-19 due to the Omicron variant have varied, with some studies suggesting robust protection similar to protection against earlier SARS-CoV-2 variants, and others suggesting reduced protection against the Omicron variant and further reductions over time as the time from booster dosing increases. 8,10-14 Additionally, questions remain about the effectiveness of booster vaccine doses and whether specific demographic and high-risk groups benefit most from COVID-19 booster doses. 15 Understanding the effectiveness of COVID-19 vaccines against severe disease caused by the Omicron variant and its lineages has been challenging, which likely plays a role in the variability of recent results that have emerged. Many hospitalized patients tested positive for SARS-CoV-2 in the first quarter of 2022; however, in part due to the high incidence of infections caused by the Omicron variant and universal testing upon admission, some fraction of these detections were likely "incidental" in patients admitted for alternative reasons and may not have represented hospitalizations due to COVID-19. 16,17 If VE is lower against milder infections compared with severe infections, incidental SARS-CoV-2 detections

may artificially reduce VE estimates against severe COVID-19, when using any COVID-19 detections among hospitalized patients as an outcome. ¹⁰ Increased time since vaccination with a primary series and widespread use of booster vaccine doses during the Omicron period further complicate distinguishing the contribution of immune evasion of the Omicron variant from waning immunity. ^{8,10}

To overcome these challenges, we evaluated the effectiveness of COVID-19 vaccines to prevent hospitalizations during the Omicron predominant period in the US, using data from patients hospitalized primarily because of COVID-19. We calculated vaccine effectiveness (VE) of a primary series plus one booster dose and a primary vaccine series alone, by time since the last vaccine dose, thus providing data to help understand the effectiveness of booster doses and the interplay of immune evasion and waning immunity during the Omicron surge. Lastly, as a complementary laboratory analysis to these clinical VE evaluations, we measured serum antibody concentrations in healthy adult volunteers to determine anti-SARS-CoV-2 responses before and after receiving booster doses.

METHODS

Setting and Design for VE Analysis

This prospective, multicenter observational assessment was conducted by the Influenza and Other Viruses in the Acutely III (IVY) Network in collaboration with the US Centers for Disease Control and Prevention (CDC). The IVY Network is a 21-hospital collaborative in the US that has published COVID-19 VE estimates iteratively throughout the pandemic (**Table S1**). The current analysis included adult patients hospitalized at IVY sites during the period of Omicron variant predominance in the Network: December 26, 2021–April 30, 2022 (with a brief pause of enrollment January 25–31, 2022 for a protocol update). Using a test-negative design, VE for the prevention of Omicron-variant COVID-19-associated hospitalization was calculated for the COVID-19 vaccines authorized for use in US: BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and Ad26.COV2 (Johnson & Johnson [Janssen]). 18-20 These

activities were reviewed by CDC, were conducted consistent with applicable federal law and CDC policy (45 C.F.R. part 46.102(I)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq), and were determined to be public health surveillance with waiver of informed consent by institutional review boards at CDC and each enrolling site.

Participants

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

Site personnel prospectively identified and enrolled hospitalized COVID-19 case-patients and concurrent test-negative control-patients. Case-patients were adults (≥18 years old) admitted to the hospital with symptomatic COVID-19 confirmed with a positive SARS-CoV-2 reverse transcriptionpolymerase chain reaction (RT-PCR) or antigen test within 14 days of symptom onset. Case-patients had one or more of the following COVID-19-associated signs or symptoms: fever, cough, shortness of breath, loss of taste, loss of smell, use of respiratory support (high flow oxygen by nasal cannula, non-invasive ventilation, or invasive mechanical ventilation) for the acute illness, or new pulmonary findings on chest imaging indicating pneumonia. Control-patients were adults hospitalized with at least one of the above signs or symptoms of COVID-like illness who tested negative for SARS-CoV-2, influenza, and respiratory syncytial virus by RT-PCR within 14 days of symptom onset. Case-control status was determined by results of both clinical SARS-CoV-2 testing at the admitting hospital as well as standardized, central laboratory RT-PCR SARS-CoV-2 testing. Patients who tested positive for SARS-CoV-2 by either clinical testing or central laboratory testing were classified as cases, while patients who tested negative by both clinical and central laboratory testing were classified as controls. Sites sought to enroll case and controlpatients in a 1:1 ratio. Case- and control-patients were enrolled within two weeks of one another and not matched on other individual patient characteristics.

Data Collection

Trained personnel at enrolling sites collected patient data on demographics, medical history, underlying health conditions (**Table S2**), COVID-19 vaccination status, laboratory findings, and clinical outcomes through patient or proxy interviews and medical record review. Patients were followed from admission until discharge, death, or hospital day 28 (whichever occurred first). Clinical outcomes included in-hospital death, invasive mechanical ventilation, supplemental oxygen therapy, vasopressor use, and intensive care unit admission. The composite outcome of death or invasive mechanical ventilation was used to identify patients with "critical COVID-19." Individual pre-existing health conditions were grouped into condition categories of cardiovascular, endocrine, gastrointestinal, hematologic, immunocompromising, neurologic, pulmonary, and renal. Verification of COVID-19 vaccination was performed for information such as dates of vaccination, vaccine products, and lot numbers using a systematic search of hospital electronic medical records, state vaccine registries, and vaccination cards (when available).

Classification of Vaccination Status

We assessed effectiveness of a primary COVID-19 vaccine series plus one booster dose and a primary series alone. ²¹ During the surveillance period, US recommendations for COVID-19 vaccine dosing for primary series and booster doses varied depending on health status (notably, presence of immunocompromising conditions), age, vaccine product, and timing of prior vaccination. While national US vaccine surveillance data do not distinguish vaccination status by medical conditions, the IVY network collects detailed clinical data to facilitate descriptions of vaccine uptake by nuanced eligibility criteria. ³ Based on CDC recommendations, we classified patients into four mutually exclusive vaccination status groups: 1) unvaccinated; 2) partially vaccinated; 3) primary series alone; 4) primary series plus one booster dose (Table S3).

Among immunocompetent individuals (i.e., those without an immunocompromising condition collected by the IVY network [Table S2]), we classified patients as completing a primary series if they received either one dose of Ad26.COV2 (Janssen) or two doses (>3-8 weeks apart) of an mRNA vaccine (BNT162b2 or mRNA-1273) with the final dose ≥14 days before illness onset. ²² Immunocompetent patients were classified as having received a booster dose if they completed a primary series and received an additional dose of any licensed COVID-19 vaccine ≥7 days prior to illness onset.

Among immunocompromised individuals, we classified patients as completing a primary series if they received either an initial Ad26.COV2 dose plus one additional COVID-19 vaccine dose (AD26.COV2 or mRNA) or three doses of an mRNA vaccine ≥7 days before illness onset. Immunocompromised patients were classified as receiving a booster dose if they completed a primary series and received an additional dose of any licensed COVID-19 vaccine product ≥7 days prior to illness onset.

Patients were classified as unvaccinated if they had never received any COVID-19 vaccine. Those who received one mRNA COVID-19 vaccine dose but did not complete a primary series were classified as partially vaccinated and excluded from this analysis. Sample size of patients who receive two booster doses was not large enough to calculate VE for a primary series plus two booster doses; thus, patients who received two booster doses were excluded from this analysis. Patients were also excluded if they received a booster dose prior to eligibility based on US recommendations (**Table S4**).

Molecular diagnosis and sequencing

Upper respiratory specimens were obtained from enrolled patients by nasal swab or saliva collection for SARS-CoV-2 testing. The samples underwent standardized RT-PCR testing at a central laboratory at Vanderbilt University Medical Center (Nashville, Tennessee) for detection of two SARS-CoV-2 nucleocapsid gene targets (N1 and N2). Samples with detection of either N1 or N2 with a cycle threshold ≤32 were shipped to the University of Michigan (Ann Arbor, Michigan) for viral whole genome

sequencing using the ARTIC Network protocol (v4.1 primer set) and an Oxford Nanopore Technologies

GridION instrument.²³ SARS CoV-2 variants and lineages are reported using the PANGO nomenclature.²⁴

Case-patients with a SARS-CoV-2 variant other than Omicron identified through sequencing were excluded from this analysis.

Statistical Analysis

VE for the prevention of COVID-19-associated hospitalization was estimated by comparing the odds of antecedent COVID-19 vaccination versus no vaccination among case- and control-patients. Adjusted odds ratios (aORs) were generated using multivariable logistic regression models with case status as the outcome, vaccination as the primary exposure, and prespecified covariables considered potential confounders: admission date (biweekly intervals), age (18–49, 50–64, and \geq 65 years), sex, self-reported race and ethnicity, and U.S. Health and Human Services region of the admitting hospital. VE was calculated as $(1 - aOR) \times 100$.

Models were stratified by vaccination group (primary series plus one booster dose or primary series alone), immunosuppression status (immunocompetent or immunocompromised), age group (18–64 versus ≥65 years), time from receipt of last vaccine dose to illness onset, and vaccine product received (Ad26.COV2, BNT162b2, or mRNA-1273). Time between last vaccine dose of a primary series and illness onset was stratified into 14–150 days and >150 days to align with current US recommendations for the timing of a first booster dose. ²⁵ Time between first booster dose and illness onset was dichotomized into 7–120 days and >120 days based on timing of eligibility for a second booster dose as recently allowed in select populations. ²⁶

Statistical differences among baseline characteristics, outcomes, and treatments were evaluated using Pearson's chi-squared test for binary or categorical variables and the Wilcoxon rank-sum test for continuous variables. Vaccine effectiveness P values were calculated by fitting a multilevel regression

model and performing a pairwise comparison across levels of categorical variables (vaccination group, vaccine product). Statistical analyses were performed using Stata 16 (College Station, TX) and GraphPad Prism version 9.3.1 for Windows (GraphPad Software, San Diego, CA).

Post-vaccination antibody responses

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

To complement the VE analysis described above, we also evaluated anti-SARS-CoV-2 antibody responses after booster doses with the BNT162b2, mRNA-1273, and Ad26.COV2 vaccine products. Healthy adult volunteers scheduled for their first booster dose were recruited at four IVY Network sites during October 5, 2021–January 28, 2022. Enrolled participants reported never having symptomatic COVID-19, either at the time of enrollment or in the past, and never testing positive for SARS-CoV-2. Serum was collected before the booster dose and then again 2-6 weeks after the dose. These serum samples were tested at CDC with the V-PLEX SARS-CoV-2 panel 2 kit (Meso Scale Diagnostics) for IgG against the spike protein (S), receptor binding domain (RBD), and nucleocapsid (N). Targets of the antibody responses were based on proteins from the USA-WA1/2020 strain. Participants with elevated anti-nucleocapsid antibody concentration (>11.8 binding antibody units [BAU] per mL) suggestive of a prior SARS-CoV-2 infection at either the pre-booster or post-booster time point were excluded. Prebooster and post-booster anti-S and anti-RBD concentrations were summarized with spaghetti plots and geometric means. Some participants had previously contributed serum specimens for antibody measurements 2-6 weeks after a primary series (i.e., after a second mRNA dose or after a first Ad26.COV2 dose) earlier in this program. 27 When available, these post-primary series antibody measurements were displayed to facilitate evaluation of antibodies in the same individual after a

Patient and public involvement

primary series, before a first booster dose, and after a first booster dose.

Patients were not involved in the original design of this study. Throughout the conduct of the study, patients were routinely engaged in the work via structured interviews conducted between research personnel and patients, which included discussions about COVID-19 and COVID-19 vaccines.

Results of the study will be disseminated to the public via announcements from the Centers for Disease Control and Prevention and via lay and social media.

RESULTS

Participants in VE Analyses

During December 26, 2021–April 30, 2022, 4,299 hospitalized patients were enrolled from 21 hospitals. 1,118 (26%) patients were excluded from the analysis, with the most common reason being partial vaccination (n=461) (**Figure S1**). 3,181 patients were included in the final analysis, including 1,572 (49%) COVID-19 case-patients and 1,609 (51%) test-negative control-patients, with a median overall age of 64 years (IQR 52–74). 1,520 (48%) included patients were female, 619 (19%) were non-Hispanic Black, 423 (13%) were Hispanic, and 654 (21%) were immunocompromised **(Table 1)**.

Of the 1,572 case-patients, 671 (43%) were unvaccinated, 654 (42%) completed a primary series alone, and 247 (16%) completed a primary series plus one booster dose. Of the 1,609 control-patients, 386 (24%) were unvaccinated, 672 (42%) completed a primary series alone, and 551 (34%) received a primary series plus one booster dose. Unvaccinated patients were younger (median 58 years [IQR 44–69]) than those who completed a primary series alone (median 65 years [IQR 54–74]), or a primary series plus one booster (median 68 years [IQR 59–78]) (p<0.001). Unvaccinated patients were less likely to have had ≥1 hospital admission in the past year than those who were vaccinated with a primary series plus one booster dose or primary series alone (p<0.001) (Table 1).

Viral whole genome sequencing was performed for 648 COVID-19 case-patients, and a SARS-CoV-2 variant was successfully identified in 508 (78%). Among those with a variant identified, 444 (87%)

were Omicron, and 64 (13%) were Delta. Patients with the Delta variant were excluded from analyses.

Of the 444 sequenced Omicron cases, 396 (89%) were BA.1 lineage and 48 (11%) were BA.2 lineage.

BA.2 became the predominant lineage during the week starting March 27, 2022 (Figure 1).

Among vaccinated patients, most received a homologous mRNA primary series (90%), with lower proportions of patients receiving Ad26.COV2 (9%) or a heterologous mRNA (1%) primary series (Figure 2). For booster dose product received, 97% of patients received an mRNA vaccine, with only 3% receiving Ad26.COV2. Most mixing of vaccine products occurred after receipt of one dose of Ad26.COV2 or after two doses of the same mRNA product.

VE against COVID-19 hospitalization

When considering all vaccine products (BNT162b2, mRNA-1273, and AD26.COV2), among immunocompetent patients, VE against COVID-19 hospitalization was higher for a primary series plus a booster (77%; 95% CI: 71–82) than a primary series alone (44%; 95% CI: 31–54) (p<0.001) (Figure 3).

Among immunocompetent patients vaccinated with either BNT162b2 (Pfizer) or mRNA-1273 (Moderna), those who received a homologous booster dose (i.e., a third dose of the same vaccine product) had significantly higher VE against COVID-19 hospitalization than those who received only a primary series.

For BNT162b2, VE for a primary series plus a booster was 80% (95% CI: 73–85%) and for a primary series alone was 46% (95% CI: 30–58%) (p<0.001). For mRNA-1273, VE for a primary series plus a booster was 77% (95% CI: 67–83) and for a primary series alone was 47% (95% CI: 30–60) (p<0.001). While the sample size of patients who received a homologous booster dose with Ad26.COV2 (Johnson & Johnson) was small (n=20), the addition of a booster dose did not appear to increase VE compared to an AD26.COV2 single dose primary series. VE against COVID-19 hospitalization for two doses of Ad26.COV2 (i.e., a booster dose following a primary Ad26.COV2 dose) was 30% (95% CI: -85–74%) and for a single dose primary series alone was 41% (95% CI: 9–62%) (p=0.665). Among heterologous booster product

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

recipients (those who received a different product for the primary series and booster dose), VE for mixed mRNA vaccine doses (i.e., any combination of BNT162b2 and mRNA-1273) was 70% (95% CI: 34-86), while VE for a primary series Ad26.COV2 plus one mRNA booster was 64% (95% CI: 35-80). VE for immunocompromised patients completing a primary series (three doses of an mRNA vaccine) was 60% (95% CI: 41–73). VE could not be estimated for a primary series plus one booster in immunocompromised patients due to a small number of participants (n=5) who received a first booster dose (i.e., a fourth mRNA vaccine dose). In analyses of VE against COVID-19 hospitalization stratified by time since the last vaccine dose, point estimates consistently showed a waning of protection at longer time points for both a primary series plus booster dose and a primary series alone. VE after a primary series for immunocompetent patients at 14–150 days (median 109 days) since the last vaccine dose was 54% (95% CI: 32–69), and at >150 days (median 279 days) was 42% (95% CI: 28–54%) . VE after a booster dose for immunocompetent patients at 7–120 days (median 69 days) following the booster dose was 80% (95%: 74-84%) and at >120 days (median 147 days) was 65% (95% CI: 47-77%). For immunocompromised patients, VE for a primary series at 14-150 days (median 91 days) was 65% (95% Cl: 46-77%) and at >150 days (median 172 days) was 48% (95% CI: 5-72%). Clinical outcomes among unvaccinated and vaccinated patients hospitalized with COVID-19 Clinical outcomes by day 28 of admission were available for the 1,361 COVID-19 case-patients admitted to hospital between December 26, 2021 and April 2, 2022; 1,117 (82%) of these patients were discharged from the hospital prior to day 28, 127 (9%) remained hospitalized at day 28, and 117 (9%) died in the hospital before day 28 (Table 2). Intensive care unit admission was more common among unvaccinated patients (34%) than vaccinated patients (26%, including 26% among those who completed a primary series alone and 26% among those who completed a primary series plus booster) (p=0.007).

The composite critical COVID-19 outcome of death or invasive mechanical ventilation was more common among unvaccinated patients (23%) than vaccinated patients (15%, including 16% among those who completed a primary series alone and 14% among those who completed a primary series plus one booster dose) (p=0.002). Among 1,257 COVID-19 case-patients with data available on in-hospital treatments, use of one or more treatment indicated for severe COVID-19 (corticosteroids, tocilizumab, or baricitinib) was more common among unvaccinated patients (72%) than vaccinated patients (59%, including 60% who completed a primary series alone and 55% who completed a primary series plus booster) (p<0.001).

Pre-booster and post-booster serum antibody results

Paired serum samples were collected before and after a COVID-19 booster dose in 63 healthy volunteers, including 33 with a BNT162b2 booster dose after a BNT162b2 primary series, 16 with an mRNA-1273 booster dose following an mRNA-1273 primary series, 8 with an Ad26.COV2 booster dose after an Ad26.COV2 primary series dose and 6 with one mRNA booster dose after an Ad26.COV2 primary series dose (Table S5). Anti-RBD and anti-S antibody concentrations were higher after compared to before the booster dose for all vaccines (Figure 4; Table S6). Post-booster anti-RBD and anti-S antibody concentrations were higher for participants who received three BNT162b2 doses and three mRNA-1273 doses compared to two Ad26.COV2 doses.

DISCUSSION

Principal Findings

In this analysis of hospitalized adults at 21 hospitals in the US during an Omicron predominant period from December 26, 2021–April 30, 2022, receipt of a COVID-19 primary vaccine series plus a booster dose provided greater protection against COVID-19 hospitalization than receipt of a primary

series alone. This added protection of a booster dose was seen across all age groups and for all three vaccine products used in the US. mRNA vaccines (BNT162b2 and mRNA-1273) provided greater protection than the Ad26.COV2 vaccine, both when considering a primary series alone and boosted vaccine regimens. These clinical vaccine effectiveness findings were supported by serology results demonstrating substantially higher anti-SARS-CoV-2 antibody titers following booster vaccine doses. These antibody and VE data support US recommendations that all eligible patients receive a booster dose to protect against severe disease from the Omicron variant.

Comparison with other studies and policy implications

estimated 77% of the adult population has received a primary series, of whom nearly half of those eligible to receive a first booster dose had not yet received it. Modest waning in protection of a primary COVID-19 vaccine series was initially demonstrated during the Delta variant period. All Our findings support the concept of waning protection for primary vaccine series for the Omicron variant as well, with a decline in protection for a primary series against COVID-19 hospitalization during the Omicron period greater than 5 months after a primary series. These data add to the growing evidence of waning effectiveness of a primary series. Despite known immune evasion features of the Omicron variant for vaccines currently available, our results show that VE substantially increased following a booster dose, consistent with results from other studies. Data from immunological studies suggest that a broadening of the immune response occurs after a booster dose, including an increase in, and adaptation of, anti-receptor binding domain-specific memory B cells, providing biologic plausibility for increased VE after a booster dose even with the highly divergent Omicron variant. Saturdate of the omicron healthy adult volunteers suggested significant increases in anti-RBD and anti-spike antibody levels 2-6 weeks after receiving one booster dose, consistent with observed differences in VE between those who received a

primary series only versus those who received one booster dose. Understanding the extent to which VE against severe Omicron disease wanes following booster doses will require the accumulation of more data over time. While some early evidence from the US, United Kingdom, and Israel have shown some decrease in effectiveness of mRNA vaccines >120 days from a first booster dose ^{10,37,38}, we found only a modest decline in VE following a booster dose in this study (from 80% at 7–120 days to 65% at >120 days).

We also observed that vaccinated patients hospitalized with COVID-19 experienced less severe outcomes than unvaccinated patients hospitalized with COVID-19, suggesting that COVID-19 vaccines result in disease attenuation and providing further rationale for COVID-19 vaccination. In this analysis, while patients who received boosted vaccine regimens were less likely to be hospitalized with COVID-19 than those who received a primary series alone, in-hospital outcomes were similar between those who received boosted regimens and a primary series alone. Additional study will be required to understand if booster doses lead to incremental disease attenuation beyond a primary series among vaccine breakthrough cases.

Our findings also suggest lower effectiveness for the adenovirus vector vaccine (Ad26.COV2) both as a primary vaccine series and as a booster dose compared to mRNA vaccines. Although mechanisms of protection against SARS-CoV-2 have not yet been established, binding antibodies correlate with protection against SARS-CoV-2, allowing for contextualization of findings from observational data. ^{27,39,40} In this analysis, the persistently low anti-spike and anti-RBD levels post-primary series dose and before a first booster dose for recipients of Ad26.COV2 compared with recipients of mRNA vaccines provide complementary understanding of the reduced effectiveness of this vaccine relative to mRNA vaccines. These findings support preferential use of mRNA vaccines both for a primary series and as a booster dose, regardless of which vaccine product was used for the primary series. ^{25,26}

Strengths and limitations

Important strengths of this study included enrollment of patients with active COVID-19 symptoms ascertained at the bedside in real-time and laboratory confirmed SARS-CoV-2 infection; these methods facilitated calculations of vaccine effectiveness to prevent symptomatic, laboratory confirmed COVID-19 hospitalization. Additionally, ascertainment of vaccination status was robust, with patient interviews combined with systematic searches of medical records and vaccines registries, which enabled precise classification of each patient's vaccination status, including the receipt of booster doses.

Furthermore, respiratory samples with SARS-CoV-2 detection underwent viral sequencing, which enabled exclusion of patients identified to have infections with a variant other than Omicron.

This analysis also had limitations. First, although several relevant confounders were controlled in VE models, residual or unmeasured confounding is possible. In particular, increases in the proportion of individuals with prior SARS-CoV-2 infection, which is associated with a degree of protection against reinfection, may have led lower VE observed in this study compared with studies from earlier in the pandemic when fewer control patients had prior natural infection. Although binding antibodies likely correlate with protection against SARS-CoV-2 infection, other immune responses including neutralizing antibodies and cellular immunity were not evaluated. Third, patients included in the antibody analysis were healthy adult volunteers and may not fully represent the clinical and demographic characteristics of those included in VE analyses. Fourth, modest sample size limited precision of some estimates, including waning of VE >120 days after a booster dose and effectiveness of Ad26.COV2, and prevented estimates for effectiveness of booster doses in immunocompromised patients. Fifth, our study was restricted to analysis of first booster doses due to second booster doses only emerging in select populations toward the end of the study period and low uptake of second boosters in the study population. Future studies on second boosters will be important.

CONCLUSION

Vaccination with a primary COVID-19 vaccine series plus a booster dose was significantly more effective than a primary series alone in preventing COVID-19 associated hospitalization during the Omicron-variant period in the US. Additionally, mRNA vaccines were more effective than the Ad26.COV2 vaccine, both as a primary series and as booster doses. Serology results support these findings by showing substantial increases in anti-SARS-CoV-2 antibody titers following booster vaccine doses, particularly with mRNA vaccines. These findings support recommendations for all eligible people aged ≥18 years to receive a booster dose of an mRNA vaccine.

NOTES

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

Contributions: Guarantors of this work include Dr. Self (protocol and data integrity), Ms. Adams (statistical analysis), Dr. Lauring (viral sequencing laboratory methods), Dr. Chappell (RT-PCR laboratory methods), Dr. Thornburg (antibody measurement methods). Contributions of each author include the following. Responsibility for decision to submit the manuscript: Self. Composed the initial manuscript draft: Adams, Rhoads, Surie, Tenforde, Self (the authors alone wrote the manuscript without outside assistance). Conceptualization of study methods: Adams, Rhoads, Surie, Gaglani, Ginde, McNeal, Ghamande, Huynh, Talbot, Casey, Mohr, Zepeski, Shapiro, Gibbs, Files, Hicks, Hager, Ali, Prekker, Frosch, Exline, Gong, Mohamed, Johnson, Srinivasan, Steingrub, Peltan, Brown, Martin, Monto, Lauring, Khan, Hough, Busse, ten Lohuis, Duggal, Wilson, Gordon, Qadir, Chang, Mallow, Rivas, Babcock, Kwon, Chappell, Halasa, Grijalva, Rice, Stubblefield, Baughman, Lindsell, Hart, Lester, Thornburg, Park, McMorrow, Patel, Tenforde, Self. Statistical analysis and data management: Adams, Tenforde, Lindsell, Hart, Zhu. Funding acquisition: Self. Critical review of the manuscript for important intellectual content: Adams, Rhoads, Surie, Gaglani, Ginde, McNeal, Ghamande, Huynh, Talbot, Casey, Mohr, Zepeski, Shapiro, Gibbs, Files, Hicks, Hager, Ali, Prekker, Frosch, Exline, Gong, Mohamed, Johnson, Srinivasan, Steingrub, Peltan, Brown, Martin, Monto, Lauring, Khan, Hough, Busse, ten Lohuis, Duggal, Wilson, Gordon, Qadir, Chang, Mallow, Rivas, Babcock, Kwon, Chappell, Halasa, Grijalva, Rice, Stubblefield, Baughman, Lindsell, Hart, Lester, Thornburg, Park, McMorrow, Patel, Tenforde, Self. The corresponding author (Dr. Self) attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. Funding: Primary funding for this work was provided by the United States Centers Disease Control and Prevention (contracts 75D30120F00002 and 75D30122C12914 to Dr. Self). Scientists from the US CDC participated in all aspects of this study, including its design, analysis, interpretation of data, writing the

report, and the decision to submit the article for publication. The REDCap data tool used in this work was supported by a Clinical and Translational Science Award (UL1 TR002243) from the National Center for Advancing Translational Sciences, National Institutes of Health.

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors (ICMJE) disclosure form. Funding for this work was provided to all participating sites by the United States Centers for Disease Control and Prevention. Samuel Brown reports grants from National Institutes of Health (NIH) and Department of Defense (DoD), participation as the DSMB chair for Hamilton Ventilators, and participation as a member of the DSMB for New York University COVID clinical trials. Jonathan Casey reports funding from NIH and DoD. Steven Chang reports consulting fees from La Jolla Pharmaceuticals, PureTech Health, and Kiniska Pharmaceuticals, payment/honoraria from La Jolla Pharmaceuticals, and participation on a DSMB for an investigator-initiated study conducted at UCLA. James Chappell reports grants and other support from NIH. Abhijit Duggal reports consulting fees from ALung technologies. Matthew Exline reports payment/honorariua from Abbott Lab for sponsored talks. D. Clark Files reports consulting fees from Cytovale and participation on a DSMB for Medpace. Anne Frosch reports grants from NIH. Manjusha Gaglani reports grants from Centers for Disease Control and Prevention (CDC), CDC-Abt Associates, CDC-Westat, and Janssen, and a leadership role as co-chair of the Infectious Disease and Immunization Committee of the Texas Pediatric Society, Texas Chapter of American Academy of Pediatrics. Kevin Gibbs reports funding from NIH/ National Heart, Lung, and Blood Institute (NHLBI) for the ACTIV-4HT NECTAR trial. Adit Ginde reports grants from NIH, DoD, AbbVie, and Faron Pharmaceuticals. Michelle Gong reports grants from NIH/NHLBI and Agency for Healthcare Research and Quality (AHRQ), consulting fees from Endpoint, a leadership role on the American Thoracic Society (ATS) executive committee and board as well as support from ATS for meeting travel expenses, and participation on a DSMB for Regeneron. Carlos Grijalva reports grants

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

from NIH, CDC, Food and Drug Administration (FDA), AHRQ, Sanofi, and Syneos Health and consulting fees from Pfizer, Merck, and Sanofi. David Hager reports grants from NIH/NHLBI for the ACTIV-4HT NECTAR trial and Incyte Corporation and participation as a DSMB chair for the SAFE EVICT Trial of vitamin C in COVID-19. Natasha Halasa reports grants from NIH, Quidel, and Sanofi and honoraria for speaking at the American Academy of Pediatrics (AAP) conference. Catherine Hough reports grants from NIH and American Lung Association (ALA) and participation as a DSMB member for iSPY COVID and Team (ANZICS). Nicholas Johnson reports grants from NIH/NHLBI/NINDS and the University of Washington Royalty Research Fund and payment for expert testimony for the Washington Department of Health. Akram Khan reports grants from United Therapeutics, Gilead Sciences, and 4D Medical and a leadership role on the guidelines committee for Chest. Jennie Kwon reports grants from NIH/NIAID. Adam Lauring reports grants from CDC, NIH/NIAID, and Burroughs Wellcome Fund and consulting fees from Sanofi and Roche. Christopher Lindsell reports grants from NIH, DoD, CDC, bioMerieux, Entegrion Inc., Endpoint Health, and AbbVie, patents for risk stratification in sepsis and septic shock, participation on DSMBs for clinical trials unrelated to the current work, a leadership role on the executive committee for the Board of Directors of the Association for Clinical and Translational Science, and stock options in Bioscape Digita. Emily Martin reports grants from Merck, CDC, and NIH and payment/honoraria from the Michigan Infectious Disease Society. Tresa McNeal reports payment/honoraria from the Society of Hospital Medicine. Arnold Monto reports grants from CDC and NIAID/NIH and participation on a DSMB for the FDA. Ithan Peltan reports grants from NIH, Janssen, Regeneron, and Asahi Kasei Pharma. Todd Rice reports grants from AbbVie Inc., consulting fees from Cumberland Pharmaceuticals, Inc. and Cytovale, Inc., membership on a DSMB for Sanofi, Inc., a leadership role as immediate past president of the American Society of Parenteral and Enteral Nutrition, and stock options in Cumberland Pharmaceuticals, Inc. Wesley Self reports receiving the primary funding for this project from the United

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

States Centers for Disease Control and Prevention, and research funding from Merck and Gilead Sciences. William Stubblefield reports grants from the NIH/NHLBI. Patient Consent: not applicable. Ethical Approval: This program was approved as a public health surveillance activity with waiver of informed consent by institutional review boards at the US Centers for Disease Control and Prevention (CDC), the program's coordinating center at Vanderbilt University Medical Center and each participating site. Data Sharing: No additional data are available. Transparency: Dr. Self affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained. Dr. Self led the development of the study protocol and participant enrollment. Ms. Adams led statistical analysis. Dr. Lauring led viral sequencing work. Dr. Chappell led RT-PCR work. Dr. Self takes responsibility for the work overall. Dissemination to participants and related patient and public communities: Results will be disseminated to relevant communities via public health announcements from the US Centers for Disease Control and Prevention, via press releases in the lay press, and public presentations by the investigators.

REFERENCES

- 631 1. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron
- 632 variant in southern Africa. *Nature*. Mar 2022;603(7902):679-686. doi:10.1038/s41586-022-04411-y
- 633 2. Lambrou AS, Shirk P, Steele MK, et al. Genomic Surveillance for SARS-CoV-2 Variants:
- 634 Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants United States, June 2021-
- 635 January 2022. MMWR Morb Mortal Wkly Rep. Feb 11 2022;71(6):206-211.
- 636 doi:10.15585/mmwr.mm7106a4
- 637 3. Centers for Disease Control and Prevention. COVID-19 Data Tracker. Accessed April 9, 2022,
- 638 https://covid.cdc.gov/covid-data-tracker/
- 639 4. Cele S, Jackson L, Khoury DS, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of
- Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv. Dec 17
- 641 2021;doi:10.1101/2021.12.08.21267417
- 642 5. Wilhelm A, Widera M, Grikscheit K, et al. Reduced Neutralization of SARS-CoV-2 Omicron
- Variant by Vaccine Sera and Monoclonal Antibodies. *medRxiv*. 2021:2021.12.07.21267432.
- 644 doi:10.1101/2021.12.07.21267432
- 645 6. Lassauniere R, Polacek C, Frische A, et al. Neutralizing Antibodies Against the SARS-CoV-2
- Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA
- Vaccine. *JAMA Netw Open*. May 2 2022;5(5):e2212073. doi:10.1001/jamanetworkopen.2022.12073
- 648 7. Andrews N, Stowe J, Kirsebom F, et al. Covid-19 Vaccine Effectiveness against the Omicron
- 649 (B.1.1.529) Variant. N Engl J Med. Mar 2 2022; doi:10.1056/NEJMoa2119451
- 650 8. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA
- 651 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and
- 652 Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance VISION
- 653 Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. Feb 18 2022;71(7):255-
- 654 263. doi:10.15585/mmwr.mm7107e2
- 655 9. Hansen CH, Schelde AB, Moustsen-Helm IR, et al. Vaccine effectiveness against SARS-CoV-2
- infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273
- vaccination series: A Danish cohort study. medRxiv. 2021:2021.12.20.21267966.
- 658 doi:10.1101/2021.12.20.21267966
- 659 10. Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines
- against Omicron and Delta hospitalisation: test negative case-control study. medRxiv.
- 661 2022:2022.04.01.22273281. doi:10.1101/2022.04.01.22273281
- 662 11. Buchan SA, Chung H, Brown KA, et al. Effectiveness of COVID-19 vaccines against Omicron or
- Delta symptomatic infection and severe outcomes. *medRxiv*. 2022:2021.12.30.21268565.
- doi:10.1101/2021.12.30.21268565
- Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron
- and Delta variants. *Nat Med*. Feb 21 2022;doi:10.1038/s41591-022-01753-y
- 667 13. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines
- 668 Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations
- Among Adults During Periods of Delta and Omicron Variant Predominance VISION Network, 10 States,
- 670 August 2021-January 2022. MMWR Morb Mortal Wkly Rep. Jan 21 2022;71(4):139-145.
- 671 doi:10.15585/mmwr.mm7104e3
- Natarajan K, Prasad N, Dascomb K, et al. Effectiveness of Homologous and Heterologous COVID-
- 673 19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-
- 674 19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults -
- VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. Apr 1
- 676 2022;71(13):495-502. doi:10.15585/mmwr.mm7113e2

- 677 15. Offit PA. Covid-19 Boosters Where from Here? *N Engl J Med*. Apr 28 2022;386(17):1661-1662.
- 678 doi:10.1056/NEJMe2203329
- 679 16. Klann JG, Strasser ZH, Hutch MR, et al. Distinguishing Admissions Specifically for COVID-19 from
- 680 Incidental SARS-CoV-2 Admissions: A National Retrospective EHR Study. *medRxiv*.
- 681 2022:2022.02.10.22270728. doi:10.1101/2022.02.10.22270728
- 682 17. Modes ME, Directo MP, Melgar M, et al. Clinical Characteristics and Outcomes Among Adults
- Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and
- 684 B.1.1.529 (Omicron) Variant Predominance One Hospital, California, July 15-September 23, 2021, and
- 685 December 21, 2021-January 27, 2022. MMWR Morb Mortal Wkly Rep. Feb 11 2022;71(6):217-223.
- 686 doi:10.15585/mmwr.mm7106e2
- 687 18. Patel MK, Bergeri I, Bresee JS, et al. Evaluation of post-introduction COVID-19 vaccine
- 688 effectiveness: Summary of interim guidance of the World Health Organization. Vaccine. Jul 5
- 689 2021;39(30):4013-4024. doi:10.1016/j.vaccine.2021.05.099
- 690 19. United States Food and Drug Administration. COVID-19 Vaccines. Updated 04/01/2022.
- 691 Accessed 04/05/2022, https://www.fda.gov/emergency-preparedness-and-response/coronavirus-
- disease-2019-covid-19/covid-19-vaccines#authorized-vaccines
- 693 20. Patel MM, Jackson ML, Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines. JAMA. Nov
- 694 17 2020;324(19):1939-1940. doi:10.1001/jama.2020.19328
- 695 21. Centers for Disease Control and Prevention. Stay Up to Date with Your COVID-19 Vaccines.
- 696 Updated April 2, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html
- 697 22. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19
- Vaccines Currently Approved or Authorized in the United States. Updated April 21, 2022. Accessed May
- 699 17, 2022, https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-
- 700 us.html
- 701 23. Quick J. nCoV-2019 sequencing protocol v3 (LoCost) V.3. 2020. Accessed May 26, 2021.
- 702 https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bp2l6n26rgge/v3
- 703 24. Rambaut A, Holmes EC, O'Toole A, et al. A dynamic nomenclature proposal for SARS-CoV-2
- lineages to assist genomic epidemiology. *Nat Microbiol*. Nov 2020;5(11):1403-1407.
- 705 doi:10.1038/s41564-020-0770-5
- 706 25. Centers for Disease Control and Prevention. COVID-19 Vaccine: Interim COVID-19 Immunization
- Schedule for Ages 5 Years and Older. Updated April 23, 2022. Accessed April 20, 2022.
- 708 https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-5yrs-
- 709 older.pdf
- 710 26. Centers for Disease Control and Prevention. Clinical Considerations Second COVID-19 Vaccine
- 711 Booster Dose. Accessed April 25, 2022, https://www.cdc.gov/vaccines/covid-19/downloads/Clinical-
- 712 Considerations-Second-COVID-19-Booster-508.pdf
- 713 27. Self WH, Tenforde MW, Rhoads JP, et al. Comparative Effectiveness of Moderna, Pfizer-
- 714 BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among
- 715 Adults Without Immunocompromising Conditions United States, March-August 2021. MMWR Morb
- 716 Mortal Wkly Rep. Sep 24 2021;70(38):1337-1343. doi:10.15585/mmwr.mm7038e1
- 717 28. Centers for Disease Control and Prevention. CDC Strengthens Recommendations and Expands
- 718 Eligibility for COVID-19 Booster Shots. Updated May 19, 2022. Accessed May 20, 2022,
- 719 https://www.cdc.gov/media/releases/2022/s0519-covid-booster-acip.html
- 720 29. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6
- months in a large integrated health system in the USA: a retrospective cohort study. Lancet. Oct 16
- 722 2021;398(10309):1407-1416. doi:10.1016/S0140-6736(21)02183-8

- 723 30. Tenforde MW, Self WH, Adams K, et al. Association Between mRNA Vaccination and COVID-19
- Hospitalization and Disease Severity. JAMA. Nov 23 2021;326(20):2043-2054.
- 725 doi:10.1001/jama.2021.19499
- 726 31. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of mRNA
- 727 vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States:
- 728 prospective observational study. BMJ. Mar 9 2022;376:e069761. doi:10.1136/bmj-2021-069761
- 729 32. Committee IMoHC-VCE. Vaccine effectiveness data on a cohort of persons vaccinated by 31-Jan-
- 730 2021 with two doses. . https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-
- 731 committee/he/files_publications_corona_two-dose-vaccination-data.pdf
- 732 33. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-
- 733 CoV-2 Infection in Qatar. N Engl J Med. Dec 9 2021;385(24):e83. doi:10.1056/NEJMoa2114114
- 734 34. Muecksch F, Wang Z, Cho A, et al. Increased Memory B Cell Potency and Breadth After a SARS-
- 735 CoV-2 mRNA Boost. *Nature*. Apr 21 2022;doi:10.1038/s41586-022-04778-y
- 736 35. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced
- protection against COVID-19 in humans. *Nat Rev Immunol*. Aug 2021;21(8):475-484.
- 738 doi:10.1038/s41577-021-00578-z
- 739 36. Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and
- 740 prevention of reinfection. *Nat Rev Immunol.* Jun 2021;21(6):395-404. doi:10.1038/s41577-021-00550-x
- 741 37. Centers for Disease Control and Prevention. COVID-19 Vaccine Effectiveness during Omicron.
- 742 Accessed April 25, 2022, https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-04-
- 743 <u>20/02-COVID-Link-Gelle</u>s-508.pdf
- 744 38. Magen O, Waxman JG, Makov-Assif M, et al. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine
- 745 in a Nationwide Setting. *N Engl J Med*. Apr 13 2022;doi:10.1056/NEJMoa2201688
- 39. Bajema KL, Dahl RM, Evener SL, et al. Comparative Effectiveness and Antibody Responses to
- 747 Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans Five Veterans Affairs
- 748 Medical Centers, United States, February 1-September 30, 2021. MMWR Morb Mortal Wkly Rep. Dec 10
- 749 2021;70(49):1700-1705. doi:10.15585/mmwr.mm7049a2
- 750 40. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273
- 751 COVID-19 vaccine efficacy clinical trial. Science. Jan 7 2022;375(6576):43-50.
- 752 doi:10.1126/science.abm3425

- 753 41. Centers for Disease Control and Prevention. Science Brief: SARS-CoV-2 Infection-induced and
- Vaccine-induced Immunity. Updated October 29, 2021. Accessed May 1, 2022,
- 755 https://www.cdc.gov/coronavirus/2019-ncov/science-briefs/vaccine-induced-immunity.html

Table 1. Baseline characteristics by vaccination and COVID-19 status—21 hospitals in 18 US states, December 26, 2021–April 30, 2022 (SARS-CoV-2 Omicron variant period)

		,	/accination statu	s	COVID-1	.9 status
	Total	Unvaccinated	Completed primary series	Primary series + booster dose	COVID-19 case-patients	Control- patients
	N=3,181	N=1,057	N=1,326	N=798	N=1,572	N=1,609
Age in years, median (IQR)	64 (52–74)	58 (44–69)	65 (54–74)	68 (59–78)	64 (52–74)	63 (52–74)
Female	1,520/3,181 (48%)	489/1,057 (46%)	622/1,326 (47%)	409/798 (51%)	740/1,572 (47%)	780/1,609 (48%)
Race & Ethnicity						
Non-Hispanic White	1,916/3,181 (60%)	603/1,057 (57%)	771/1,326 (58%)	542/798 (68%)	933/1,572 (59%)	983/1,609 (61%)
Non-Hispanic Black	619/3,181 (19%)	217/1,057 (21%)	266/1,326 (20%)	136/798 (17%)	287/1,572 (18%)	332/1,609 (21%)
Hispanic, any race	423/3,181 (13%)	156/1,057 (15%)	192/1,326 (14%)	75/798 (9%)	236/1,572 (15%)	187/1,609 (12%)
Non-Hispanic, all other races	179/3,181 (6%)	60/1,057 (6%)	82/1,326 (6%)	37/798 (5%)	95/1,572 (6%)	84/1,609 (5%)
Other ^a	44/3,181 (1%)	21/1,057 (2%)	15/1,326 (1%)	8/798 (1%)	21/1,572 (1%)	23/1,609 (1%)
US census region ^b						
Northeast	732/3,181 (23%)	214/1,057 (20%)	302/1,326 (23%)	216/798 (27%)	397/1,572 (25%)	335/1,609 (21%)
South	1,072/3,181 (34%)	401/1,057 (38%)	464/1,326 (35%)	207/798 (26%)	527/1,572 (34%)	545/1,609 (34%)
Midwest	647/3,181 (20%)	221/1,057 (21%)	255/1,326 (19%)	171/798 (21%)	313/1,572 (20%)	334/1,609 (21%)
West	730/3,181 (23%)	221/1,057 (21%)	305/1,326 (23%)	204/798 (26%)	335/1,572 (21%)	395/1,609 (25%)
≥1 hospital admissions in past year	1,565/3,121 (50%)	441/1,027 (43%)	718/1,304 (55%)	406/790 (51%)	690/1,532 (45%)	875/1,589 (55%)
Self-reported prior laboratory- confirmed SARS-CoV-2 infection	345/2,974 (12%)	120/997 (12%)	147/1,252 (12%)	78/725 (11%)	115/1,487 (8%)	230/1,487 (15%)
No. of chronic medical conditions,	2 (1–3)	2 (1–3)	2 (2–3)	2 (1–3)	2 (1–3)	2 (1–3)

median (IQR) ^c						
Immunocompromising condition ^d	654/3,181 (21%)	184/1,057 (17%)	465/1,326 (35%)	5/798 (1%)	318/1,572 (20%)	336/1,609 (21%)
Obesity (≥30 kg/m² BMI)	1,306/3,097 (42%)	461/1,035 (45%)	525/1,301 (40%)	320/761 (42%)	654/1,531 (43%)	652/1,566 (42%)
Vaccine product received for primary series						
BNT162b2 (Pfizer-BioNTech)	1,154/2,124 (54%)		740/1,326 (56%)	414/798 (52%)	503/901 (56%)	651/1,223 (53%)
mRNA-1273 (Moderna)	762/2,124 (36%)		469/1,326 (35%)	293/798 (37%)	300/901 (33%)	462/1,223 (38%)
Mixed mRNA	17/2,124 (1%)		7/1,326 (1%)	10/798 (1%)	5/901 (1%)	12/1,223 (1%)
Ad26.COV2 (Johnson & Johnson)	191/2,124 (9%)		110/1,326 (8%)	81/798 (10%)	93/901 (10%)	98/1,223 (8%)
Vaccine product received for booster dose						
BNT162b2 (Pfizer-BioNTech)	460/798 (58%)			460/798 (58%)	142/247 (57%)	318/551 (58%)
mRNA-1273 (Moderna)	318/798 (40%)			318/798 (40%)	96/247 (39%)	222/551 (40%)
Ad26.COV2 (Johnson & Johnson)	20/798 (3%)			20/798 (3%)	9/247 (4%)	11/551 (2%)
Omicron lineage						
BA.1	396/444 (89%)	163/177 (92%)	189/207 (91%)	44/60 (73%)	396/444 (89%)	
BA.2	48/444 (11%)	14/177 (8%)	18/207 (9%)	16/60 (27%)	48/444 (11%)	

Abbreviations: BMI = Body mass index; IQR = interguartile range

^a Other includes self-reported race and ethnicity as other or non-Hispanic, or patients for whom information on race and ethnicity was unavailable.

b Hospitals by region included Northeast: Baystate Medical Center (Springfield, Massachusetts), Beth Israel Deaconess Medical Center (Boston, Massachusetts), Montefiore Medical Center (Bronx, New York); South: Vanderbilt University Medical Center (Nashville, Tennessee), University of Miami Medical Center (Miami, Florida), Emory University Medical Center (Atlanta, Georgia), Johns Hopkins Hospital (Baltimore, Maryland), Wake Forest University Baptist Medical Center (Winston-Salem, North Carolina), Baylor Scott & White Health (Temple, Texas); Midwest: University of Iowa Hospitals and Clinics (Iowa City, Iowa), University of Michigan Hospital (Ann Arbor, Michigan), Hennepin County Medical Center (Minneapolis, Minnesota), Barnes-Jewish Hospital (St. Louis, Missouri), Cleveland Clinic (Cleveland, Ohio), Ohio State University Wexner Medical Center (Columbus, Ohio); West: Stanford University Medical Center (Stanford, California), UCLA

- Medical Center (Los Angeles, California), UCHealth University of Colorado Hospital (Aurora, Colorado), Oregon Health & Science University Hospital (Portland, Oregon), Intermountain Medical Center (Murray, Utah), University of Washington (Seattle, Washington).
- ^c Chronic medical conditions included: cardiovascular disease, neurologic disease, pulmonary disease, gastrointestinal disease, endocrine disease, kidney disease, hematologic disease, malignancy, immunosuppression not captured in other categories, autoimmune condition, or other condition (sarcoidosis, amyloidosis, or unintentional weight loss ≥4.5 kg [10 lb] in the last 90 days).
- d Immunocompromising conditions included: active solid organ cancer (active cancer defined as treatment for the cancer or newly diagnosed cancer in the past 6 months), active hematologic cancer (such as leukemia, lymphoma, or myeloma), HIV infection without AIDS, AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid organ transplant, immunosuppressive medication, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, or inflammatory bowel disease, including Crohn's disease or ulcerative colitis.


Table 2. In-hospital clinical outcomes and treatments for adults hospitalized with COVID-19 during December 26, 2021–April 2, 2022 (the SARS-CoV-2 Omicron variant period), by vaccination status.

Outcome	Total	Unvaccinated	Primary vaccine series alone	Primary vaccine series plus booster	P-value ^a
Status at 28 days following admission, No. / Total (%)					0.032
Remained hospitalized	127/1,361 (9%)	65/621 (10%)	55/570 (10%)	7/170 (4%)	
Discharged	1,117/1,361 (82%)	493/621 (79%)	475/570 (83%)	149/170 (88%)	
Died	117/1,361 (9%)	63/621 (10%)	40/570 (7%)	14/170 (8%)	
Admitted to intensive care unit, No. / Total (%)	406/1,359 (30%)	212/621 (34%)	149/568 (26%)	45/170 (26%)	0.007
Any oxygen support, No. / Total (%)	1,022/1,361 (75%)	488/621 (79%)	410/570 (72%)	124/170 (73%)	0.023
HFNC	320/1,361 (24%)	176/621 (28%)	120/570 (21%)	24/170 (14%)	<0.001
NIPPV	179/1,361 (13%)	94/621 (15%)	69/570 (12%)	16/170 (9%)	0.092
IMV	208/1,361 (15%)	125/621 (20%)	66/570 (12%)	17/170 (10%)	<0.001
ECMO	18/1,361 (1%)	15/621 (2%)	3/570 (1%)	0/170 (0%)	0.005
Vasopressors, no. (%)	208/1,361 (15%)	114/621 (18%)	77/570 (14%)	17/170 (10%)	0.008
New renal replacement therapy, no. (%)	56/1,361 (4%)	31/621 (5%)	22/570 (4%)	3/170 (2%)	0.16
Venous thromboembolic event, No. (%) ^b	108/1,361 (8%)	60/621 (10%)	38/570 (7%)	10/170 (6%)	0.092
Stroke, No. (%)	20/1,361 (1%)	11/621 (2%)	6/570 (1%)	3/170 (2%)	0.56
Myocardial infarction, No. (%)	35/1,361 (3%)	15/621 (2%)	13/570 (2%)	7/170 (4%)	0.39
Composite of death or IMV, no. (%)	255/1,361 (19%)	141/621 (23%)	90/570 (16%)	24/170 (14%)	0.002
Any of the following therapeutics used for severe COVID-19, No. / Total (%)	812/1,257 (65%)	404/561 (72%)	318/533 (60%)	90/163 (55%)	<0.001
Corticosteroids	808/1,257 (64%)	403/561 (72%)	316/533 (59%)	89/163 (55%)	<0.001
Tocilizumab	48/1,257 (4%)	28/561 (5%)	16/533 (3%)	4/163 (2%)	0.14
Baricitinib	90/1,257 (7%)	64/561 (11%)	26/533 (5%)	0/163 (0%)	<0.001
Anti-SARS-CoV-2 Monoclonal Antibodies	29/1,257 (2%)	11/561 (2%)	16/533 (3%)	2/163 (1%)	0.32


Abbreviations: ECMO = extracorporeal membrane oxygenation; HFNC = high-flow nasal cannula; ICU = intensive care unit; IMV = invasive mechanical ventilation; NIPPV = nasal intermittent positive-pressure ventilation

- 780 ^a Statistical differences were evaluated using Pearson's chi-squared test for binary or categorical variables.
- 781 Statistical significance was determined using a p-value threshold of 0.05.
- 782 b Deep vein thrombosis and/or pulmonary embolism

Figure 1. SARS-CoV-2 Omicron lineage by admission week among 1,572 COVID-19 case-patients enrolled during December 26, 2021–April 30, 2022 (with a pause in enrollment January 25–31, 2022). Sequenced Omicron variants were grouped into BA.1 (B.1.1.529, BA.1, BA.1.1, BA.1.15, BA.1.17) and BA.2 (BA.2, BA.2.1, BA.2.3) lineages. Non-Omicron case-patients (Delta variant, B.1.1.519) confirmed through sequencing were excluded from the analysis (n=64) and not displayed in this figure. Of 444 patients with a sequence-confirmed Omicron variant infection, 396 (89%) had BA.1 and 48 (11%) had BA.2. Low sequencing totals in late January reflect a pause in IVY network enrollment during January 25–31, 2022 during a protocol update.



793 794



Product	Dose 1, n/N (%)	Dose 2, n/N (%)	Dose 3, n/N (%)	Dose 4, n/N (%)
BNT162b2 (Pfizer-BioNTech)	1,163/2,124 (55)	1,202/2,014 (60)	724/1,183 (61)	3/4 (75%)
mRNA-1273 (Moderna)	770/2,124 (36)	792/2,014 (39)	459/1,183 (39)	1/4 (25%)
Ad26.COV2 [Janssen (Johnson & Johnson)]	191/2,124 (9)	20/2,014 (1)	0/1,183 (0)	0/4 (0%)

Figure 3. Vaccine effectiveness (VE) for prevention of COVID-19 hospitalization in the US during a period of SARS-CoV-2 Omicron variant predominance, December 26, 2021 through April 30, 2022. Vaccine effectiveness for a primary vaccine series plus one booster dose is displayed in red while vaccine effectiveness for a primary series alone is displayed in blue.

	Com	pleted primary s	eries	Prima	y series + booste	er dose
	No. of vaccinated COVID-19 case- patients/total no. of COVID- 19 case-	No. of vaccinated control- patients/ total no. of control-	Vaccine effectiveness,	No. of vaccinated COVID-19 case- patients/total no. of COVID- 19 case-	No. of vaccinated control- patients/ total no. of control-	Vaccine effectiveness,
Group	patients (%)	patients (%)	% (95% CI) ^a	patients (%)	patients (%)	% (95% CI) ^a
By immunocompromising condition ^b	452/4000/45	400/725 /56	44/24 54)	245 (004 (24)	E40/06E/63\	77 (74 02)
Immunocompetent	453/1009 (45)	408/725 (56)	44 (31–54)	245/801 (31)	548/865 (63)	77 (71–82)
By age group	226/574/201	222/462/50	20/10 [2]	97/425 (20)	222/462/50	72 (61, 90)
18-64 years By number of chronic conditions ^d	226/574 (39)	233/463 (50)	38 (19–52)	87/435 (20)	232/462 (50)	72 (61–80)
0 conditions	55/160 (34)	32/81 (40)	22 (-52–60)	13/118 (11)	24/73 (33)	73 (22–90)
≥1 conditions	171/414 (41)	201/382 (53)	42 (21–57)	74/317 (23)	208/389 (53)	73 (22–30)
≥65 years	227/435 (52)	175/262 (67)	47 (26–63)	158/366 (43)	316/403 (78)	81 (73–87)
By vaccine product ^e	227/433 (32)	173/202 (07)	47 (20 03)	130/300 (43)	310/403 (70)	01 (73 07)
BNT162b2 (Pfizer-BioNTech)	240/796 (30)	206/523 (39)	46 (30–58)	119/675 (18)	276/593 (47)	80 (73–85)
mRNA-1273 (Moderna)	151/707 (21)	151/468 (32)	47 (30–60)	83/639 (13)	189/506 (37)	77 (67–83)
Mixed mRNA	2/558 (0)	1/318 (0)	40 (-668–95)	10/566 (2)	26/343 (8)	70 (34–86)
Ad26.COV2 (Janssen)	60/616 (10)	50/367 (14)	41 (9–62)	9/565 (2)	11/328 (3)	30 (-85–74)
Ad26.COV2 (Janssen) + mRNA				23/579 (4)	37/354 (10)	64 (35–80)
By time between last dose and illness onset ^c				, , ,		
14-150 days	69/625 (11)	67/384 (17)	54 (32–69)			
>150 days	384/940 (41)	341/658 (52)	42 (28-54)			
7-120 days				167/723 (23)	394/711 (55)	80 (74-84)
>120 days				78/634 (12)	154/471 (33)	65 (47–77)
Immunocompromised	201/316 (64)	264/333 (79)	60 (41-73)	2/117 (2)	3/72 (4)	
By time between last dose and illness onset ^c						
14-150 days	144/259 (56)	197/266 (74)	65 (46–77)			
>150 days	57/172 (33)	67/136 (49)	48 (5-72)			
By Omicron lineage						
BA.1 (December 26, 2021–March 26, 2022)	183/342 (54)	547/843 (65)	53 (37–64)	43/202 (21)	399/695 (57)	83 (75–89)
BA.2 (March 27–April 30, 2022)	15/25 (60)	125/215 (58)		13/23 (57)	152/242 (63)	

^a Multivariable logistic regression models were used to determine vaccine effectiveness, with vaccine status as the primary independent variable, case status as the dependent variable, and the following covariates: admission date (biweekly intervals), age (18–49, 50–64, and ≥65 years), sex, self-reported race and ethnicity, and U.S. Health and Human Services region of the admitting hospital. Models stratified by age group were adjusted using age in years as a continuous variable. VE was not calculated for certain subgroups due to limited sample size.

- b Immunocompromising conditions included: active solid organ cancer (active cancer defined as treatment for the cancer or newly diagnosed cancer in the past 6 months), active hematologic cancer (such as leukemia, lymphoma, or myeloma), HIV infection without AIDS, AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid organ transplant, immunosuppressive medication, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, or inflammatory bowel disease, including Crohn's disease or ulcerative colitis.
- ⁶ Time between last vaccine dose of a primary series and illness onset was stratified into 14–150 days and >150 days to align with current US recommendations. Time between booster dose and illness onset was stratified into 7–120 days and >120 days based on timing between a first booster dose and second booster recently recommended to be allowed in select populations.
- disease, malignancy, immunosuppression not captured in other categories, autoimmune condition, or other condition (sarcoidosis, amyloidosis, or unintentional weight loss ≥4.5 kg [10 lb] in the last 90 days).
- Evaccinated case- and control-patients counted under BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and Ad26.COV2 (Johnson & Johnson [Janssen]) received
 homologous product series for all doses. Mixed mRNA includes those receiving any heterologous combination of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna).
 Ad26.COV2 (Janssen) + mRNA received Ad26.COV2 for their first dose, followed by one dose of any mRNA product.

Figure 4. Spaghetti plots of serum antibody concentrations to the SARS-CoV-2 receptor binding domain (anti-RBD) (panel A) and spike protein (anti-spike) (panel C) among healthy adult volunteers before and 2–6 weeks after receiving COVID-19 booster doses, October 5, 2021–January 28, 2022. Targets of the antibody responses were based on proteins from the USA-WA1/2020 strain. Antibody concentrations 2–6 weeks after a primary series is also displayed for the subset of participants with anti-RBD (panel B) and anti-spike (panel D) measurements available from prior participation in the program. Each participant is represented with a single line connecting the antibody concentration at each time point. The Pfizer-BioNTech group included 33 participants who received three doses of BNT162b2, including 9 who had antibody measurements after the second dose. The Moderna group included 16 participants who received three mRNA-1273 doses, including 7 who had antibody measurements after the second dose. The Johnson and Johnson (J&J) group included 8 participants who received two doses of Ad26.COV2, including 3 who had antibody measurements after the first dose. The J&J + mRNA group included 6 participants who received an mRNA vaccine (BNT162b2 or mRNA-1273) booster dose after a single Ad26.COV2 primary series dose, including 2 who had antibody measurements after the initial Ad26.COV2 dose. The data accompanying this figure are shown in Table S6.

